Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACDC vs RADX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACDC Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ACDC Overall Winner 6-Pillar Tally: ACDC 5 – 1 RADX Matrix Metrics: ACDC 8 – 2 RADX

As of Nov 20, 2026, ProFrac Holding Corp. (ACDC) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACDC carries a Unified Composite Score of 51.1/100 (HOLD) at $2.75 (16.2x Forward P/E, -8.1% operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin).

  • Technical & Structure Timing Caution: ACDC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACDC vs RADX
ACDC NASDAQ Head-to-Head Winner
ProFrac Holding Corp. Class A Common Stock
Oil & Gas Field Services, Nec
$2.75
-6.62% 1D
Market Cap $536.4M
TTM Revenue $1.90B
Forward P/E 16.2x
Beta / 30D Vol 1.65β · 148% Vol
Unified Composite Score
51.1 / 100 HOLD
Tech 63.0 Fund 61.0 Flow 57.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.7%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $3.65 · SMA50: $4.17
RADX NASDAQ
Radiopharm Theranostics Limited American Depositary Shares
Pharmaceutical Preparations
$0.63
-6.33% 1D
Market Cap $10.6M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 0.52β · 109% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.5%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.86 · SMA50: $1.15

6-Pillar Scorecard Institutional Category Breakdown (ACDC 5 – 1 RADX)

Columns: Metric · ACDC · RADX
1. Valuation Multiples ACDC
Forward P/E 16.2x N/M
Trailing P/E 16.2x N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x 0.8x
2. Growth & Scale ACDC
Revenue Growth (YoY) +26.8% -36.9%
Earnings Growth (YoY) -99.1% +0.0%
TTM Revenue (USD) $1.90B $13M
Market Cap $536.4M $10.6M
3. Profitability & Quality ACDC
Gross Margin 21.8% N/A
Operating Margin -8.1% -411.6%
Net Profit Margin -20.4% 0.0%
Return on Equity (ROE) -42.9% -174.7%
4. Balance Sheet & Cash Flow ACDC
Cash Generation (TTM) -$16M -$50M EBITDA
Cash Flow Margin -0.8% N/A
Net Cash / Leverage $1.11B Net Debt (2.28x D/E) $1.48 Book/Sh · -174.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RADX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 83.3% (5th %ile) N/A (N/A)
Put/Call OI Skew 35.20x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ACDC
OpEx & R&D Intensity 29.9% of Rev ($567M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Oil & Gas Equipment & Services Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACDC (8) vs RADX (2)
Institutional Metric ACDC RADX Criterion Row Edge
Market Capitalization
Scale
$536.4M $10.6M Larger Scale ACDC
Trailing P/E Ratio
Valuation
16.2x N/M Lower Multiple ACDC
Forward P/E Ratio
Valuation
16.2x N/M Lower Multiple ACDC
Revenue Growth (YoY)
Growth
+26.8% -36.9% Higher Growth ACDC
Operating Margin (TTM)
Profitability
-8.1% -411.6% Higher Margin ACDC
Net Profit Margin
Profitability
-20.4% 0.0% Higher Margin RADX
Return on Equity (ROE)
Capital Efficiency
-42.9% -174.7% Higher ROE ACDC
52-Week Range Position
Momentum
2% ($3–$8) 0% ($1–$16) Stronger Trend ACDC
Beta / 30D Volatility
Risk Regime
1.65β · 148% Vol 0.52β · 109% Vol Lower Realized Risk RADX
Unified Institutional Score
Composite Signal
51.1 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite ACDC
Trailing 12M Revenue (USD)
Operating Scale
$1.90B $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
21.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($1.11B Net Debt (2.28x D/E)) -$50M EBITDA ($1.48 Book/Sh · -174.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACDC +4.88 pp
ACDC: -28.76% · RADX: -33.64%
3M Horizon ACDC +31.21 pp
ACDC: -42.95% · RADX: -74.16%
6M Horizon ACDC +21.72 pp
ACDC: -64.52% · RADX: -86.24%
1Y Horizon ACDC +63.6 pp
ACDC: -22.75% · RADX: -86.35%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACDC vs RADX. Trailing 12-month operating profitability (ACDC -8.1% vs RADX -411.6%) and valuation multiples (ACDC 16.2x vs RADX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACDC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.90B
Gross Margin21.8%
Op. Margin-8.1%
ROE / Fwd P/E-42.9% · 16.2x
RADX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross MarginN/A
Op. Margin-411.6%
ROE / Fwd P/E-174.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACDC BREAKDOWN
52d in phase · OBV DISTRIBUTION
Current IV 83.3%
IV Percentile 5th %ile
Put/Call OI Skew 35.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACDC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RADX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RADX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACDC Moat Profile Cyclical / Execution-Driven Positioning
Oil & Gas Equipment & Services Operator
Competes within the Oil & Gas Equipment & Services value chain with $536.4M market capitalization and -8.1% operating margin.
OpEx & R&D Reinvestment 29.9% of Rev ($567M)
90D Engineering Disclosures 0 Published
RADX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $10.6M market capitalization and -411.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACDC vs RADX Key Questions & Quantitative Answers

As of Nov 20, 2026, ProFrac Holding Corp. (ACDC) is the stronger overall head-to-head candidate over Radiopharm Theranostics Limited (RADX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACDC carries a Unified Composite Score of 51.1/100 (HOLD) at $2.75 (16.2x Forward P/E, -8.1% operating margin), whereas RADX carries 41.1/100 (SELL) at $0.63 (N/M Forward P/E, -411.6% operating margin). Technical & Structure Timing Caution: ACDC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.4); meanwhile RADX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACDC leads the Growth & Scale pillar: ACDC posts +26.8% YoY revenue growth and -99.1% YoY earnings growth on $1.90B TTM revenue (21.8% gross margin, -8.1% operating margin), compared with RADX at -36.9% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (N/A gross margin, -411.6% operating margin). On trailing 12-month operating scale, ACDC generates $1.90B in USD-normalized revenue versus $13M for RADX. In operating R&D and SG&A reinvestment, ACDC deploys 29.9% of Rev ($567M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RADX.

ACDC screens cheaper on headline valuation multiples. ACDC trades at 16.2x Forward P/E, 16.2x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-0.8% FCF margin), whereas RADX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACDC (-42.9% ROE) versus RADX (-174.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ACDC carries 83.3% implied volatility (5th %ile, Compressed (<25th %ile)), a 35.20x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 148% Vol realized risk). By comparison, RADX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 109% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.